SSX6P

Across TCGA pan-cancer cohorts, SSX6P Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated SSX6P data layer compared with 20 for mass-spec protein.

The strongest signal is observed in adrenocortical carcinoma (ACC), where higher SSX6P Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated SSX6P expression acts as an unfavorable survival marker, although some lineages such as SKCM show a favorable association.

ACC, STAD, and ESCA are the cancer types where SSX6P Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
ACC	DFS	Median	All	0.010	0.667	<.001	45	view →
STAD	OS	Median	III,IV	0.074	0.633	<.001	24	view →
ESCA	OS	Median	II,III,IV	0.130	0.703	<.001	24	view →
COAD	OS	Median	III,IV	0.140	0.792	<.001	15	view →
LGG	OS	Median	All	0.407	0.811	.037	6	view →
SKCM	DFS	Median	All	1.000	0.217	.029	1	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

SSX6P–ACC (DFS)

Open the ACC breakdown →